Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$6.12 -0.3%	$4.91	$3.30 ▼ $13.23	$746.32M	0.83	656,687 shs	536,153 shs
IOVA Iovance Biotherapeutics	$2.24 -3.0%	$2.55	$1.64 ▼ $12.51	$748.01M	0.86	8.92 million shs	8.78 million shs
KALV KalVista Pharmaceuticals	$12.96 -1.0%	$12.35	$7.30 ▼ $15.50	$644.32M	-0.01	444,820 shs	768,473 shs
NVCT Nuvectis Pharma	$8.41 -4.8%	$9.31	$4.44 ▼ $11.80	$175.72M	-0.16	129,768 shs	122,453 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	0.00%	+2.51%	+30.49%	+34.51%	-53.35%
IOVA Iovance Biotherapeutics	0.00%	+9.27%	+27.27%	-37.60%	-73.74%
KALV KalVista Pharmaceuticals	0.00%	-9.75%	+11.15%	+2.86%	+4.94%
NVCT Nuvectis Pharma	0.00%	-4.97%	-9.37%	-4.97%	+26.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMTX Immatics	2.5965 of 5 stars	3.6	3.0	0.0	3.4	1.7	0.0
IOVA Iovance Biotherapeutics	4.6385 of 5 stars	4.3	1.0	4.2	2.2	4.2	1.3
KALV KalVista Pharmaceuticals	3.8837 of 5 stars	3.6	0.0	4.4	2.6	2.5	0.6
NVCT Nuvectis Pharma	2.928 of 5 stars	3.5	0.0	0.0	3.2	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	3.20	Buy	$14.67	139.65% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	493.75% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	91.62% Upside
NVCT Nuvectis Pharma	3.00	Buy	$17.00	102.14% Upside

Current Analyst Ratings Breakdown

Latest NVCT, IOVA, KALV, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$144.15M	5.16	N/A	N/A	$2.88 per share	2.13
IOVA Iovance Biotherapeutics	$212.68M	3.52	N/A	N/A	$2.28 per share	0.98
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$104.98M	-$0.17	N/A	N/A	N/A	-47.94%	-15.90%	-9.38%	8/12/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$444.04M	-$1.24	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	8/6/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-103.92%	-88.06%	7/10/2025 (Estimated)
NVCT Nuvectis Pharma	-$22.26M	-$1.13	N/A	N/A	N/A	N/A	-155.80%	-104.02%	8/5/2025 (Estimated)

Latest NVCT, IOVA, KALV, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/6/2025	Q1 2025	NVCT Nuvectis Pharma	-$0.30	-$0.27	+$0.03	-$0.27	N/A	N/A
3/27/2025	Q4 2024	IMTX Immatics	-$0.03	$0.48	+$0.51	$0.48	$16.16 million	$15.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	3.98	3.98
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
KALV KalVista Pharmaceuticals	N/A	6.87	6.87
NVCT Nuvectis Pharma	N/A	2.74	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
IOVA Iovance Biotherapeutics	77.03%
KALV KalVista Pharmaceuticals	N/A
NVCT Nuvectis Pharma	96.77%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
IOVA Iovance Biotherapeutics	10.30%
KALV KalVista Pharmaceuticals	10.50%
NVCT Nuvectis Pharma	30.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	260	121.55 million	115.42 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	267.90 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.23 million	Optionable
NVCT Nuvectis Pharma	8	20.89 million	12.41 million	Not Optionable

NVCT, IOVA, KALV, and IMTX Headlines

Recent News About These Companies

Millennium Management LLC Reduces Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

June 13 at 3:07 AM | marketbeat.com

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2025 | globenewswire.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 Shares

May 14, 2025 | insidertrades.com

Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases 2,650 Shares of Stock

May 10, 2025 | insidertrades.com

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

May 9, 2025 | zacks.com

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

May 9, 2025 | finance.yahoo.com

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | ...

May 6, 2025 | gurufocus.com

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | gurufocus.com

Nuvectis Pharma, Inc. Reports Promising Phase 1a Data for NXP900 and Secures $15.5 Million Financing

May 6, 2025 | quiverquant.com

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025 | globenewswire.com

Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile

May 1, 2025 | nasdaq.com

Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 5.45%

April 30, 2025 | aaii.com

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

April 30, 2025 | insidermonkey.com

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

April 29, 2025 | globenewswire.com

Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation

April 3, 2025 | msn.com

Nuvectis Pharma initiated with a Buy at Maxim

April 3, 2025 | markets.businessinsider.com

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

March 26, 2025 | markets.businessinsider.com

Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 11.52%

March 26, 2025 | aaii.com

Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation

March 18, 2025 | msn.com

Nuvectis Pharma initiated with a Buy at Laidlaw

March 17, 2025 | markets.businessinsider.com

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

March 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, IOVA, KALV, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

$6.12 -0.02 (-0.33%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.04 -0.08 (-1.37%)

As of 06/13/2025 05:53 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Iovance Biotherapeutics NASDAQ:IOVA

$2.24 -0.07 (-3.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.24 -0.01 (-0.22%)

As of 06/13/2025 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

KalVista Pharmaceuticals NASDAQ:KALV

$12.96 -0.13 (-0.99%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$13.00 +0.04 (+0.30%)

As of 06/13/2025 07:29 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$8.41 -0.42 (-4.76%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$8.32 -0.09 (-1.07%)

As of 06/13/2025 07:14 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time